Citation Tools
PDFRegular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1314 Trilaciclib, an intravenous cyclin-dependent kinase 4/6 inhibitor, enhances antitumor responses by modulating T cells
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 1314 Trilaciclib, an intravenous cyclin-dependent kinase 4/6 inhibitor, enhances antitumor responses by modulating T cells